Altimmune to Present Pemvidutide Clinical Data at 60th EASD Annual Meeting

GAITHERSBURG, Md., Sept. 03, 2024 - Altimmune, Inc., a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker symbol ALT, has announced an important milestone in its research. The company has revealed that findings from a Phase 2, MRI-based body composition sub-study involving pemvidutide for overweight and obesity subjects will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain. The presentation, titled "Pemvidutide preserves lean body mass during weight loss in patients with overweight and obesity: results of a phase 2, MRI-based body composition sub-study," will be delivered by Dr. Sarah Browne, Vice President of Clinical Development at Altimmune. This session is scheduled for Tuesday, September 10, 2024, at 1:45 pm CEST.

Pemvidutide is an innovative, investigational therapy that operates as a peptide-based GLP-1/glucagon dual receptor agonist. It is currently being developed to treat obesity and metabolic dysfunction-associated steatohepatitis (MASH). The dual activation of GLP-1 and glucagon receptors is believed to emulate the synergistic effects of diet and exercise in weight reduction. The GLP-1 receptor activation helps suppress appetite, while the glucagon receptor activation is thought to boost energy expenditure. Additionally, glucagon is known for its direct impact on hepatic fat metabolism, leading to significant reductions in liver fat and serum lipid levels.

Clinical trials of pemvidutide have shown promising results so far. Administered once a week, pemvidutide has exhibited substantial weight loss, along with significant reductions in triglycerides, LDL cholesterol, liver fat content, and blood pressure. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of MASH, highlighting its potential importance in addressing this ailment.

The development of pemvidutide is part of Altimmune's broader mission to create next-generation peptide-based therapeutics. Pemvidutide has recently concluded the MOMENTUM Phase 2 trial focused on obesity and is currently being evaluated in the ongoing IMPACT Phase 2b trial for MASH.

Altimmune is committed to advancing innovative treatments that target complex health conditions. The company's focus on peptide-based therapeutics aims to bring new, effective options to patients struggling with obesity and metabolic diseases. For further details on their research and developments, one can visit their official website.

The presentation at the European Association for the Study of Diabetes meeting represents a significant opportunity for Altimmune to share their findings with a broader scientific audience, potentially paving the way for future advancements in the treatment of obesity and MASH.